Access Program Information
To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular
Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.
To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular
Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.